LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial
Results suggest short-term improvements in mood following microdosed LSD in people with depression, warranting confirmation in controlled trials. It provides the pharmacokinetic parameters of 8 μg of LSD in a sample of people with depression and indicates no tolerance or sensitisation to repeated microdoses of LSD, despite incremental dose titration.
Authors
- Nathan Allen (ORCID: https://orcid.org/0000-0001-7876-819X)
- Robin J. Murphy (ORCID: https://orcid.org/0000-0002-9571-0050)
- Malak Alshakhouri (ORCID: https://orcid.org/0000-0002-2633-3159)
- Anna Forsyth (ORCID: https://orcid.org/0000-0002-3283-2691)
- Dimitri Henriques Daldegan-Bueno
- Lisa Reynolds (ORCID: https://orcid.org/0000-0002-9609-2135)
- David B Menkes (ORCID: https://orcid.org/0000-0003-3760-7896)
- Soo Hee Jeong (ORCID: https://orcid.org/0000-0002-5984-1280)
- Rachael L. Sumner (ORCID: https://orcid.org/0000-0002-2652-4617)
- C Donegan (ORCID: https://orcid.org/0009-0005-6936-4587)
- William Evans
- Nicholas Hoeh
- Frederick Sundram
- Suresh Muthukumaraswamy
Institutions
- Statistics New Zealand (NZ)
- University of Auckland (NZ)
- Auckland University of Technology (NZ)
Publication Details
- Journal
- Progress in Neuro-Psychopharmacology and Biological Psychiatry
- Published
- 2026-02-18
- DOI
- https://doi.org/10.1016/j.pnpbp.2026.111645
- Citations
- 1
- Primary Topic
- Psychedelics and Drug Studies
- Type
- article
- Field-Weighted Citation Impact
- 44.11